Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Investigating the Therapeutic Potential of Targeting Slc25a19 to Treat Acute Myeloid Leukemia (AML)
EF 2025-26
Résumé
Acute Myeloid Leukemia (AML) is a common form of blood cancer, affecting more than a thousand Canadians each year. When diagnosed, patients typically receive chemotherapy, or a stem-cell transplant if eligible. However, even with these treatment options, the disease has a very poor 5-year survival rate of only 23%. The main challenge for effective AML treatment is that there are several forms of AML, depending on the mutations each patient presents. Accordingly, one method to counteract the ineffectiveness of current therapies is to harness the power of the patient's own immune system to target and destroy their cancer cells. Previous studies in the Mercier Lab have identified one protein that, when removed, activates the immune system to kill the AML cells. This protein, SLC25A19, is a vitamin B1 transporter that plays a role in metabolism. Hence, the main objective for this project is to characterize AML cells without this transporter, investigating their growth, metabolism, and immune system interactions, compared to AML cells containing the transporter. These will be tested in both leukemia cells grown in the lab and in mice. We hypothesize that removing the transporter enhances the immune system's recognition of these cancer cells, hence making it easier for the immune cells to detect and destroy these AML cells, and could work alongside existing treatment options for an improved and more effective combination therapeutic intervention. Overall, the findings from these experiments can help uncover a novel therapeutic approach to improve patient outcomes and survival rates, especially in older patients that cannot tolerate standard chemotherapeutic interventions.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573068
Name
Salam Omar
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Therapeutic Potential of Targeting Slc25a19 to Treat Acute Myeloid Leukemia (AML)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer; Crispr-Cas9; Gene Therapy; Hematology; Immunology; Leukemia; Metabolism; Molecular Biology; Pharmacology; Translational Research
Abstract
Acute Myeloid Leukemia (AML) is a common form of blood cancer, affecting more than a thousand Canadians each year. When diagnosed, patients typically receive chemotherapy, or a stem-cell transplant if eligible. However, even with these treatment options, the disease has a very poor 5-year survival rate of only 23%. The main challenge for effective AML treatment is that there are several forms of AML, depending on the mutations each patient presents. Accordingly, one method to counteract the ineffectiveness of current therapies is to harness the power of the patient's own immune system to target and destroy their cancer cells. Previous studies in the Mercier Lab have identified one protein that, when removed, activates the immune system to kill the AML cells. This protein, SLC25A19, is a vitamin B1 transporter that plays a role in metabolism. Hence, the main objective for this project is to characterize AML cells without this transporter, investigating their growth, metabolism, and immune system interactions, compared to AML cells containing the transporter. These will be tested in both leukemia cells grown in the lab and in mice. We hypothesize that removing the transporter enhances the immune system's recognition of these cancer cells, hence making it easier for the immune cells to detect and destroy these AML cells, and could work alongside existing treatment options for an improved and more effective combination therapeutic intervention. Overall, the findings from these experiments can help uncover a novel therapeutic approach to improve patient outcomes and survival rates, especially in older patients that cannot tolerate standard chemotherapeutic interventions.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Salam, Omar
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~